Experience delivered

Successfully obtained a groundbreaking decision from the High Court in London, in which it awarded Actavis declarations of non-infringement in relation to multiple European designations of Lilly's patent for the anti-cancer drug, pemetrexed. This is the first time that the High Court has exercised jurisdiction in relation to foreign designations of a European patent. This paves the way for parties to bring proceedings in relation to multiple designations of European patents in a single court, provided that validity is not in issue. The case has been viewed by many as a "dress rehearsal" for the forthcoming Unified Patent Court (UPC), with one court deciding multiple decisions at once – giving the market an indication of how the UPC might impact on future patent registration, infringement and litigation in Europe. Our involvement in this precedent-setting case consolidates our position at the forefront of patent litigation in Europe and demonstrates our commitment to finding innovative solutions to our clients' biggest problems.

Representing world-leading developer of innovative medical technologies ConvaTec in a case before the Court of Appeal in the UK, whereby the Court upheld the previous decision validating ConvaTec’s patent for its innovative design and manufacturing process for producing silver wound dressings.

We continuously advise Attana AB, a pioneer in the development of QCM biosensors for analysis of biomolecular interactions, on corporate, commercial (negotiating, reviewing and drafting contracts) and IP matters (patents and trademarks). Their biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characterics of biomulecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

Representing market-leading Sanofi in various pan-European litigations against a number of pharmaceutical companies, including in patent infringement and nullity proceedings regarding Sanofi’s blockbuster product blood thinner Plavix - the world’s second-biggest selling drug.

Advising Elder Pharmaceuticals, one of the fastest growing pharmaceutical companies in India, on its acquisition of AIM-listed Neutrahealth plc for £12.2 million.

Advising Mumbai-based crop protection productions company Indofil Industries on a pan-European acquisition of a leading European Mancozeb business, under the Dithane brand, from Dow Agro Sciences LLC.

Advising a privately-owned industry leader in animal nutrition on the acquisition, including structuring, negotiation and implementation, of a Spanish company recognised as a world leader in natural feed and food carotenoid pigments, essential oils, anti-caking agents and mold inhibitors.

Assisting US medical device company, Lanx, on the establishment of a new EU based affiliate, which included helping the client identify and comply with all regulatory requirements to market its products in Europe. We provided the client with comprehensive EU-wide regulatory advice with input from all of Bird & Bird’s European offices.